Focan C, Le Hung S, Bays-Gallaix R, Frere M H, Demonceau G, Mbuyamba P, Claessens J J
Cancer Treat Rev. 1983 Sep;10 Suppl A:103-10. doi: 10.1016/s0305-7372(83)80014-0.
A randomised trial has compared the sequential administration of ifosfamide (with its urinary antidote mesna) combined with methotrexate (or 5-FU in adenocarcinomas) and vinblastine (protocol I) or combined with adriamycin and vincristine (protocol II) in advanced lung cancer. In 29 evaluable cases the results were not influenced by the protocol nor by the histology of the tumors (oat cell v non-oat cell) or the clinical stage (limited v extensive). An overall response rate of 58.6% was obtained (100% in the oat cell and anaplastic carcinomas, 44% in adenocarcinomas, 50% in squamous cell carcinomas) with a clear prolongation of survival in responding groups, whatever the clinical stage.
一项随机试验比较了异环磷酰胺（及其尿路解毒剂美司钠）序贯联合甲氨蝶呤（腺癌中为5-氟尿嘧啶）和长春碱（方案I）或联合阿霉素和长春新碱（方案II）用于晚期肺癌的疗效。在29例可评估病例中，结果不受方案、肿瘤组织学类型（燕麦细胞癌与非燕麦细胞癌）或临床分期（局限期与广泛期）的影响。总体缓解率为58.6%（燕麦细胞癌和间变性癌为100%，腺癌为44%，鳞状细胞癌为50%），无论临床分期如何，缓解组的生存期均有明显延长。
